Characteristic | Biologic-naĆÆve RA (nā=ā8) | Non-RA control (nā=ā10) | P-value* |
---|---|---|---|
Age, years, mean | 55.1 (16.5) | 53.2 (16.0) | 0.81 |
Female, % | 62.5% | 70.0% | 1.0 |
Race+, % | |||
Ā Caucasian Ā Non-Caucasian Ā Ā African American Ā Ā Hispanic Ā Ā Indian Ā Ā Unknown | 50% 50% 25% 12.5% 12.5% 0% | 30% 70% 10% 10% 0% 50% | 0.63 |
BMI (kg/m2) | 32.6 | ā | Ā |
Diabetes mellitus | 0% | ā | Ā |
Smoking history | |||
Ā Current | 12.5% | ā | Ā |
Ā Former | 37.5% | ā | Ā |
Ā Never | 50% | ā | Ā |
RA disease characteristics | |||
Ā Remission, % | 75% | ā | ā |
Ā Autoantibody status | |||
Ā Ā RF positive, % | 75% | ā | ā |
Ā Ā ACPA positive, % | 75% | ā | ā |
Ā ESR mm/h, mean | 23.38 (17.73) | ā | ā |
Ā CRP mg/L, mean | 4.26 (1.64) | ā | ā |
Ā RAPID3 score, mean | 10.42 (5.71) | ā | ā |
Ā Medication history | |||
Ā Ā DMARDs, % | 100% | ā | ā |
Ā Ā Glucocorticoids, % | 0% | ā | ā |
Ā Ā Biologic agents | |||
Ā Ā Ā TNF-inhibitor, % | 0% | ā | ā |
Ā Ā Ā Other, % | 0% | ā | ā |
Number of caries, mean | 3 (3.85) | 4.4 (7.07) | 0.62 |
Probing depth, mean (mm) | |||
Ā Shallow sites (PDāā¤ā3 mm) | 2.58 | 2.08 | 0.02 |
Ā Deep sites (PDāā„ā4 mm) $ | 4.00 | 3.65 | 0.47 |
Global PD status | |||
Ā Healthy, % | 12.5% | 0% | 0.54 |
Ā Periodontitis stage I, % | 37.5% | 40% | |
Ā Periodontitis stage II, % | 12.5% | 40% | |
Ā Periodontitis stage III, % | 37.5% | 20% |